Optum Appears in 26.9% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.

Answer Capsule

In November 2026, Optum appeared in 146 of 542 AI answers included in the Online Pharmacies benchmark (26.94%). It received 109 recommendations (20.11%), with 46 Top 3 placements and 3 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.

Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.

Current AI visibility

Questions This Section Answers

• How do Optum mentions, recommendations and placements compare with its Online Pharmacies peers?

Optum recorded 146 mentions (26.94%) and 109 recommendations (20.11%) across 542 answers included in the benchmark. Top 3 placements numbered 46; first-place recommendations numbered 3. Framing among its mentions was 109 positive, 37 neutral and 0 negative.

Optum is mentioned in roughly a quarter of the benchmark answers and recommended in about a fifth, so its reach is real but well behind the largest pharmacy brands. The more telling gap is position: it earns many recommendations but very few first-place placements, meaning answers often include Optum without leading with it.

Framing is not the problem. Almost every mention is worded positively, with no negative framing recorded. That suggests the opportunity lies in strengthening how answers position Optum against alternatives, not in repairing tone. We would build a scorecard that separates reach, recommendation and placement so the client can see where the shortfall sits.

What changed since last month

Questions This Section Answers

• How did Optum counts and coverage differ across the available monthly snapshots?

Only months with verified results are shown. Monthly sample coverage is listed in Methodology.

From October 2026 to November 2026, Optum's mention count fell from 157 to 146, while its recommendation count rose from 68 to 109. The recommendation rate was 10.59% and 20.11% respectively.

Across the three recorded months, Optum's mention count moved down while its recommendation count moved up, and the recommendation rate rose accordingly. The first-place count stayed low throughout. These are separate monthly samples, so the movement describes what was recorded rather than a trend we can attribute to any cause.

The comparability limit matters here: each month drew on a different set of answers, and a different answer total does not explain why counts or rates moved. We would treat the November result as a fresh reading and watch the next months before drawing conclusions about direction.

Step 1. Measure

Questions This Section Answers

• What should the agency measure and verify first for Optum?

AI answers contained 0 conflicting claims about Optum: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No conflicting claims about Optum were recorded in the captured answers, so there is no fact-check queue to work through at present. That is a clean starting position rather than a guarantee, since new answers can introduce new claims.

We would still set up a visibility comparison against the leading pharmacy brands and a standing list of claims to verify, so the client can see where it stands and catch disputes early. The ratings would guide fact-checking priority; they would not by themselves show that any company or publisher made an error.

Step 2. Make the website consistent

Questions This Section Answers

• Which recorded claim differences about Optum should be verified before proposed page edits?

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

This part of the analysis returned no results, so there are no disputed topics to work from yet. Any apparent conflict in an answer would need its entity, date and source resolved before it could be treated as a real inconsistency.

We would propose conditional page briefs: draft guidance prepared in advance, held until current primary-source verification confirms the facts. Where a conflict turns out to be a date difference or a mismatched company, it stays out of the correction queue. This keeps the client from acting on unverified AI wording.

Step 3. Align the external narrative

Questions This Section Answers

• Which cited third-party pages are relevant to fact review for Optum?

These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.

The cited pages selected for review are mostly Optum Rx addresses, with the main site drawing the most citation appearances. None of them is linked to a conflicting claim in the captured answers, so there is no obvious correction target.

We would review these pages against current primary sources and prepare evidence-backed requests only where a genuine gap is confirmed. A citation does not establish that a page influenced an answer, and we cannot assume publisher control or error. Requests would be framed as suggestions, with responses recorded separately from confirmed edits.

Step 4. Optimize priority company pages

Questions This Section Answers

• Which observed Optum website pages should receive review briefs?

The company's website was cited 70 times across 24 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.

Optum's own pages were cited across many distinct addresses, with the medication delivery page drawing by far the most appearances and appearing in both benchmark and recommending answers. That makes it the natural first candidate for a page brief.

Briefs would use approved facts and the audience questions observed in the research, and we would check existing coverage before proposing anything new. A cited page is not automatically one that accompanied a recommendation, so we would treat citation frequency as a signal for review rather than proof of influence.

Step 5. Publish around buyer questions

Questions This Section Answers

• Which observed buyer questions support content briefs for Optum?

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

The recorded questions cluster around mail order pharmacy choice, free or delivered prescriptions, savings programs and discount cards. Optum appears in answers to most of these, and in several it is also recommended, which suggests the topics are already within reach.

We would turn these into content briefs covering mail order comparisons, delivery options and savings programs, checking existing pages first. These are recorded answer observations, not search volume or verified demand, so the briefs would be validated against the client's own audience evidence before publication.

Our 90-day action plan

Questions This Section Answers

• How should the agency sequence the proposed Optum work and judge completion?

The first month establishes the baseline scorecard, a scoped fact-review register and a shortlist of pages and sources, each with an owner and review status. The second month produces approved page briefs and justified publisher requests, with confirmed edits, no-change decisions and responses logged separately.

The third month delivers buyer-content briefs and a fresh scorecard. Completed work would be reported apart from measured answer outcomes, and we would not claim that any intervention caused a visibility gain. Reviewers sign off at each stage before work moves forward.

Methodology

Questions This Section Answers

• How are Optum answer metrics and citation populations defined?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 542 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 5446 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

July 2026 measured a different set of companies, so it is excluded from this comparison. August 2026 measured a different set of companies, so it is excluded from this comparison.

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

The report covers a single month, and the exact collection dates for the original answers are unverified. Recommendation requires both endorsement and positive wording, and placement counts sit inside recommendations rather than adding to them. Answers can mention several companies, so company counts cannot be summed into distinct answers.

Monthly samples differ, so comparisons show how recorded results changed, not why. Cited pages and disputed claims still need independent verification before any action.

Our first three priorities

First, verify the facts behind Optum's own high-citation pages, starting with medication delivery, before any brief is approved. Second, prepare evidence-backed publisher requests only where a genuine gap is confirmed, keeping unverified or ambiguous matches out of the queue.

Third, build buyer-question content around mail order choice, delivery and savings programs, checking existing coverage first. Throughout, we would keep reach, recommendation and placement as separate measures and report completed work apart from measured outcomes, so the client sees progress without overclaiming.